Last reviewed · How we verify

Amlodipin — Competitive Intelligence Brief

Amlodipin (Amlodipin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipin (Amlodipin) — Boehringer Ingelheim.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amlodipin TARGET Amlodipin Boehringer Ingelheim marketed Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6
Norvasc amlodipine Pfizer Inc. marketed Calcium channel blocker (dihydropyridine) Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6 1992-07-31

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipin — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: